AI transforms outpatient surgery through smarter planning and safer care. "BCC Research examines how AI is improving surgical planning, real-time monitoring, risk prediction and workflow efficiency, helping outpatient providers deliver safer, faster and more coordinated care." September 09, 2026 14:03 ET | Source: BCC Research LLC Boston, Sept. 09, 2026 (GLOBE NEWSWIRE) - Artificial intelligence is fundamentally reengineering the economics and clinical outcomes of outpatient surgical care, as accelerating investment, maturing digital infrastructure, and evolving regulatory frameworks converge to drive enterprise-scale adoption across ambulatory surgery centers (ASCs), hospital outpatient departments, and robotic-assisted surgical platforms globally. BCC Research's latest analysis, AI Impact on Outpatient Surgical Procedures - BCC Pulse Report (AIT191A), maps the investment landscape, emerging technology categories, adoption trends, and competitive dynamics shaping this high-growth sector. Key Findings - Significant capital deployment is accelerating AI integration across the outpatient surgical care continuum. CMR Surgical secured $200 million from SoftBank Vision Fund, GE HealthCare Ventures, and Ally Bridge to scale its AI-augmented Versius robotic system, while Caresyntax attracted $180 million from Silver Lake Partners to advance AI-powered surgical video analytics and intraoperative performance benchmarking - signaling strong institutional confidence in the commercial viability of surgical AI platforms. - North America and Europe are leading enterprise AI adoption, anchored by flagship health system deployments. Cleveland Clinic expanded enterprise-wide AI deployment across perioperative care and outpatient surgical services in 2025, encompassing predictive risk models, AI-assisted imaging interpretation, and digital post-procedure monitoring. Mayo Clinic scaled its enterprise AI platform in 2023 to support ambulatory surgery scheduling, patient risk stratification, and imaging automation, establishing benchmarks for system-wide integration. - Rising patient and payer demand for same-day discharge is the primary structural driver of AI adoption. Growing preference for minimally invasive outpatient surgery is increasing demand for AI platforms that analyze recovery indicators, vital signs, and risk scores to enable safe same-day discharge without elevating readmission risk. Simultaneously, value-based care models are incentivizing health systems to adopt AI analytics that generate measurable reductions in complications, length of stay, and cost per procedure - directly supporting reimbursement optimization and value-based contracting. - Operational efficiency demands within high-volume ASC settings are catalyzing investment in AI scheduling, supply chain, and predictive maintenance tools. ASCs operating on tight financial margins require AI-driven solutions that reduce idle time, prevent unexpected equipment failures, and optimize procedural throughput - creating durable commercial demand for platforms addressing scheduling optimization, inventory management, and real-time equipment performance monitoring. - Six distinct AI technology categories are emerging as the dominant investment frontiers: AI-Powered Predictive Analytics for Perioperative Risk Stratification, AI-Driven Predictive Maintenance for Surgical Equipment, Real-Time AI-Enabled Patient Monitoring Systems, AI-Integrated Robotic and Image-Guided Surgical Systems, AI-Powered Intelligent Surgical Scheduling and Workflow Optimization, and AI-Enabled Supply Chain and Inventory Management. - The competitive landscape spans surgical robotics, analytics platforms, and large-scale ASC operators. Key players include CMR Surgical, Caresyntax, Asensus Surgical, Moon Surgical, Medical Microinstruments, OneStep, Quibim, United Surgical Partners International, SCA Health, Surgery Partners, AMSURG, Regent Surgical Health, American Vision Partners, ResMed, Mayo Clinic, and Cleveland Clinic. Strategic Implications Widespread EHR adoption and integrated hospital information systems have established the structured data foundation necessary for AI model training and deployment at scale, accelerating the transition of AI applications from pilot projects to full institutional implementation. Regulatory progress - including FDA and EMA guidance on Software as a Medical Device (SaMD) and real-world evidence - is reducing development uncertainty and encouraging sustained investment in clinical data infrastructure and lifecycle monitoring programs. Government-funded digital transformation initiatives across Asia-Pacific, Europe, and the Middle East are further expanding the addressable market, with deployments reported at institutions spanning the University of Tokyo Hospital, Cambridge University Hospitals, Centre Hospitalier Universitaire Vaudois, Peking Union Medical College Hospital, and hospitals across Saudi Arabia, UAE, and Brazil. Despite this momentum, structural headwinds persist. Regulatory pathways for AI-enabled surgical technologies remain evidence-intensive, requiring demonstrated performance across diverse patient populations and protections against algorithmic bias - extending development timelines and increasing costs. Clinician confidence gaps post-approval, post-discharge monitoring limitations inherent to same-day care settings, and data heterogeneity across multicenter trials present ongoing friction points that could slow commercial uptake even for cleared platforms. Investment Considerations For investors, the outpatient surgical AI sector offers a compelling intersection of structural healthcare economics, rising capital deployment, and expanding addressable infrastructure. Early-stage opportunities are concentrated in perioperative risk stratification, intraoperative analytics, and robotic platform integration - as evidenced by Quibim's $50 million Series A and OneStep's $36 million raise from General Catalyst, Tiger Global, and Breakthrough Energy Ventures. Partnerships between surgical device manufacturers, health technology companies, hospital networks, and ambulatory care providers - including Asensus Surgical's strategic integration with Google Cloud - are accelerating innovation in connected surgical ecosystems. Investors should monitor regulatory clearance timelines, real-world evidence accumulation, and ASC network expansion strategies as key value inflection points. Infrastructure constraints in Southeast Asian and African markets represent near-term limitations on global scalability but signal significant longer-horizon upside as digital health investment expands. About the Report AI Impact on Outpatient Surgical Procedures - BCC Pulse Report (AIT191A) provides qualitative analysis of AI adoption trends, investment activity, emerging technology categories, competitive dynamics, and strategic deployment patterns across the outpatient surgical care landscape globally. About BCC Research BCC Research provides objective, unbiased measurement and assessment of market opportunities with detailed market research reports. Our experienced industry analysts assess growth trends, identify and evaluate new and changing market opportunities, and provide critical information and innovative decision support tools to help inform the strategic decision-making process. For media inquiries, email [email protected] or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher.

Vector Science & Therapeutics and Caresyntax announce real-world evidence partnership for VectorMist. Jul 17, 2026, 08:10 ET * Caresyntax will design and operate a multi-phase real-world evidence program for Vector, culminating in a prospective comparative registry across a network of partner surgical facilities. * The program will compare postoperative outcomes (opioid utilization, length of stay, and patient-reported pain) between standard of care and procedures using VectorMist and The LASSO Protocol. * The parties have agreed to explore extending the same evidence architecture across Vector's broader portfolio, including its peptide therapeutics programs, subject to a separate agreement. MEQUON, Wis. and SAN FRANCISCO, July 17, 2026 /CNW/ - Vector Science & Therapeutics Corp. (TSXV: PAIN) ("Vector") and Caresyntax, a global leader in surgical intelligence and real-world evidence, today announced a strategic partnership to build the clinical evidence infrastructure supporting VectorMist(TM), Vector's localized atomized drug delivery platform, and The LASSO Protocol(TM)(Laparoscopic Atomization System for Sparing Opioids). VectorMist is designed to deliver atomized medication directly to the surgical site during laparoscopic procedures, providing targeted pain control at the source and reducing reliance on systemic opioids in postoperative recovery. The LASSO Protocol is the clinical protocol built on the VectorMist platform. Under the agreement, Caresyntax will design and operate a multi-phase real-world evidence program across a network of partner surgical facilities. The program begins with baseline data collection on current standard-of-care procedures, capturing postoperative opioid utilization, length of stay, and patient-reported pain scores. A comparative phase then measures outcomes from VectorMist procedures against that baseline. The program culminates in a prospective comparative registry across the participating surgical network, giving institutions the ability to benchmark their outcomes against peer and cohort performance on a standardized data model. The partnership positions VectorMist as a data-enabled surgical platform rather than a device-only offering. Every institution deploying VectorMist will contribute to and benefit from a growing body of real-world outcomes evidence, a value proposition aligned with the outcomes accountability that hospital purchasing committees and value-based care programs now require. The parties have also agreed to explore extending the evidence architecture beyond VectorMist. Vector and Caresyntax intend to evaluate applying the same approach (standardized data capture, comparative analysis, and registry-based benchmarking) across Vector's broader portfolio, including its peptide therapeutics programs. A common evidence infrastructure would allow each program to draw on shared methodology, data governance, and clinical network rather than standing up parallel data efforts. Any such expansion would be subject to a separate agreement between the parties. "Every surgical procedure should generate evidence that makes the next one better," said Dr. Brad Worthington, Chief Medical Officer of Vector. "This partnership builds that feedback loop into VectorMist from day one. Rigorous, comparative real-world evidence on opioid utilization, length of stay, and patient-reported pain is how we earn the confidence of surgeons and the institutions they serve." "Vector is doing what the next generation of medtech companies must do - building the evidence engine alongside the product," said Dr. Bruce Ramshaw, Chief Medical Informatics Officer of Caresyntax. "By applying our clinical quality improvement methodology from the very first case, this program will give surgeons and institutions a continuous, comparative view of real-world performance and turn every VectorMist procedure into measurable clinical insight." The real-world evidence program directly supports Vector's thought leadership and clinical education strategy for The LASSO Protocol, including a planned white paper series establishing sustained opioid sparing as a distinct clinical category. About Vector Science & Therapeutics Corp. Vector Science & Therapeutics Corp. is a medical technology and therapeutic delivery company developing technologies intended to improve how pharmaceutical agents, peptides, biologics and other therapeutic compounds are delivered to target tissues. The Company's intellectual property portfolio spans advanced transdermal delivery, precision catheter systems, localized pain management, regenerative medicine, pancreatic oncology, smart wound care, lyophilized pharmaceutical systems and next-generation therapeutic delivery technologies. Vector Science & Therapeutics Corp. is headquartered in Mequon, Wisconsin. About Caresyntax Caresyntax powers surgical performance and outcomes through AI-enabled analytics, real-world evidence, and workflow integration tools. Its regulatory-grade platform supports health systems, payers, and life sciences companies globally. To learn more visit www.caresyntax.com/rwe Forward-Looking Statements This press release contains forward-looking statements concerning Vector Science & Therapeutics Corp.'s intellectual property, technology platforms, development programs, potential clinical applications, strategic opportunities and commercialization plans. These statements are based on current expectations and are subject to risks and uncertainties. Technologies described by the Company may require additional research, development, preclinical or clinical evaluation and applicable regulatory review before commercialization. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. SOURCE Vector Sciences & Therapeutics Vector Science & Therapeutics, Bill Jackson, Chief Executive Officer, [email protected]